Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Diagnosing Natriuretic Peptide Deficiency

Phase 1

Completed

Conditions: Healthy
Lean

Interventions: Drug: Dexamethasone

First Posted Date: 2017-01-30

Last Posted Date: 2019-06-20

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 10

Registration Number: NCT03035929

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Quality of Recovery After Dexamethasone, Ondansetron or Placebo Intrathecal Morphine Administration

Phase 4

Completed

Conditions: Fractures, Bone
Nausea and Vomiting, Postoperative
Pruritus
Morphine Adverse Reaction
Satisfaction, Personal

Interventions: Drug: Saline
Drug: Dexamethasone
Drug: Ondansetron

First Posted Date: 2017-01-30

Last Posted Date: 2020-03-19

Lead Sponsor: Pontificia Universidade Catolica de Sao Paulo

Target Recruit Count: 135

Registration Number: NCT03035942

Locations: 🇧🇷
Santa Lucinda Hospital, Sorocaba, SP, Brazil

The Effect of Dexamethasone Added to Bupivacain in Nasal Surgery

Phase 4

Completed

Conditions: Nasal Surgery

Interventions: Drug: Bupivacaine
Drug: Dexamethasone

First Posted Date: 2017-01-30

Last Posted Date: 2017-06-07

Lead Sponsor: Ataturk University

Target Recruit Count: 60

Registration Number: NCT03036605

Locations: 🇹🇷
Ataturk University, Erzurum, Yakutiye, Turkey

The Effect of Dexamethasone on Pain After Total Knee Replacement Surgery

Phase 4

Terminated

Conditions: Pain, Postoperative
Arthroplasty, Knee Replacement

Interventions: Drug: Sodium Chloride, (24)NaCl 0,9%
Drug: Dexamethasone

First Posted Date: 2017-01-27

Last Posted Date: 2018-11-29

Lead Sponsor: University of Oulu

Target Recruit Count: 27

Registration Number: NCT03034733

Locations: 🇫🇮
Oulu University Hospital, Oulu, OYS, Finland

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Phase 3

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: Placebo for dexamethasone
Drug: Rovalpituzumab tesirine
Drug: Placebo for rovalpituzumab tesirine
Drug: Dexamethasone

First Posted Date: 2017-01-26

Last Posted Date: 2021-07-29

Lead Sponsor: AbbVie

Target Recruit Count: 748

Registration Number: NCT03033511

Locations: 🇺🇸
Parkland Health and Hosp Syste /ID# 170933, Dallas, Texas, United States
🇺🇸
LA Hem-Oncology Med Group /ID# 156717, Los Angeles, California, United States
🇺🇸
Thomas Jefferson University /ID# 156719, Philadelphia, Pennsylvania, United States

and more 305 locations

A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone

First Posted Date: 2017-01-26

Last Posted Date: 2020-11-06

Lead Sponsor: Enceladus Pharmaceuticals BV

Target Recruit Count: 7

Registration Number: NCT03033316

Clinical Trial of Gut Microbiota in the Management of Immune Thrombocytopenia

Phase 2

Conditions: Immune Thrombocytopenia

Interventions: Drug: Probiotic Agent
Drug: Dexamethasone

First Posted Date: 2017-01-26

Last Posted Date: 2017-01-26

Lead Sponsor: Shandong University

Target Recruit Count: 60

Registration Number: NCT03033199

Locations: 🇨🇳
Shandong University Qilu hospital, Jinan, Shandong, China

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Plasmacytoma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Dexamethasone Sodium Phosphate
Procedure: Echocardiography
Drug: Lenalidomide
Drug: Navtemadlin

First Posted Date: 2017-01-26

Last Posted Date: 2024-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT03031730

Locations: 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸
University of Texas at Austin, Austin, Texas, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Relapsed and Refractory Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2017-01-24

Last Posted Date: 2022-05-25

Lead Sponsor: Amgen

Target Recruit Count: 126

Registration Number: NCT03029234

Locations: 🇨🇳
Guangzhou First Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
West China Hospital, Sichuang University, Chengdu, Sichuan, China

and more 14 locations

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2017-01-24

Last Posted Date: 2024-12-18

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 25

Registration Number: NCT03030261

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States
🇨🇦
University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy